摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

双环[4.2.0]辛-1(6),2,4-三烯-8-甲酰氯 | 1473-47-8

中文名称
双环[4.2.0]辛-1(6),2,4-三烯-8-甲酰氯
中文别名
——
英文名称
Benzocyclobuten-1-carbonsaeure-chlorid
英文别名
Bicyclo[4.2.0]octa-1,3,5-triene-7-carbonyl chloride
双环[4.2.0]辛-1(6),2,4-三烯-8-甲酰氯化学式
CAS
1473-47-8
化学式
C9H7ClO
mdl
——
分子量
166.607
InChiKey
FRRRANOWXWHKJE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    103 °C
  • 密度:
    1.312±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2916209090

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury
    摘要:
    Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.
    DOI:
    10.1021/jm9013696
  • 作为产物:
    参考文献:
    名称:
    二价碳中间体的化学-IV:苯基卡宾对各种键类型的分子间和分子内反应性比较
    摘要:
    通过竞争实验苯基碳烯,从phenyldiazomethane生成的手段,已经被证明是近似相等反应性的苯环(以形成phenylcycloheptatriene)和脂族CH 2个键的,为大约六倍以上反应性脂族CH 2个键比脂族CH 2键,并且对芳族CH键非常不活泼。这些数据已被用来帮助解释两个先前报道的结果1 b,1 c分子内对应物;它们还用于解释2-正丁基苯基重氮甲烷的分解,该分解生成比例大约为6:5:1的三种环状产物2-乙基茚满,2-甲基四氢萘和苯并双氢呋喃,以及第四种烃产物1- (邻甲苯基)-丁烯-2,代表卡宾反应的新模式。研究了温度和光源对2-正丁基苯基重氮甲烷分解产物比例的影响。
    DOI:
    10.1016/s0040-4020(01)92713-9
点击查看最新优质反应信息

文献信息

  • Synthesis of 3,3-Disubstituted Oxindoles by Palladium-Catalyzed Asymmetric Intramolecular α-Arylation of Amides: Reaction Development and Mechanistic Studies
    作者:Dmitry Katayev、Yi-Xia Jia、Akhilesh K. Sharma、Dipshikha Banerjee、Céline Besnard、Raghavan B. Sunoj、E. Peter Kündig
    DOI:10.1002/chem.201301572
    日期:2013.9.2
    their performance is compared. One of them, L8, containing a tBu and a 1‐naphthyl group at the stereogenic centre, proved superior and was very efficient in the asymmetric synthesis of fifteen new spiro‐oxindoles and three azaspiro‐oxindoles often in high yields (up to 99 %) and enantioselectivities (up to 97 % ee; ee=enantiomeric excess). Three palladacycle intermediates resulting from the oxidative addition
    掺有手性N-杂环卡宾(NHC)配体的钯配合物催化酰胺的不对称分子内α-芳基化反应,生成3,3-二取代的羟吲哚。已经进行了全面的DFT研究,以深入了解这种转变的机制。氧化添加被证明是决定速率的,还原消除是对映选择性的决定。详细介绍了七个新的NHC配体的合成,并比较了它们的性能。其中之一,L8,在立体异构中心含有一个t Bu和一个1-萘基,被证明是优越的,并且在不对称合成15个新的螺-氧杂吲哚和3个氮杂-螺氧杂吲哚中通常非常高的收率(高达99) %)和对映选择性(高达97%  ee; ee =对映体过量)。分离并氧化了[Pd(NHC)]到芳基卤化物键中形成的三种palladacycle中间体,并对其结构进行了表征(X射线)。使用这些中间体作为催化剂,表明烯烃添加剂在增加周转次数和频率中起着重要的作用。
  • Chemistry of bivalent carbon intermediates—IV
    作者:C.D. Gutsche、G.L. Bachman、R.S. Coffey
    DOI:10.1016/s0040-4020(01)92713-9
    日期:1962.1
    By means of competition experiments phenylcarbene, generated from phenyldiazomethane, has been shown to be approximately equally reactive to the benzene ring (to form phenylcycloheptatriene) and to aliphatic CH2 bonds, to be approximately six times more reactive to aliphatic CH2 bonds than to aliphatic CH2 bonds, and to be very unreactive toward aromatic CH bonds. These data have been used as aids
    通过竞争实验苯基碳烯,从phenyldiazomethane生成的手段,已经被证明是近似相等反应性的苯环(以形成phenylcycloheptatriene)和脂族CH 2个键的,为大约六倍以上反应性脂族CH 2个键比脂族CH 2键,并且对芳族CH键非常不活泼。这些数据已被用来帮助解释两个先前报道的结果1 b,1 c分子内对应物;它们还用于解释2-正丁基苯基重氮甲烷的分解,该分解生成比例大约为6:5:1的三种环状产物2-乙基茚满,2-甲基四氢萘和苯并双氢呋喃,以及第四种烃产物1- (邻甲苯基)-丁烯-2,代表卡宾反应的新模式。研究了温度和光源对2-正丁基苯基重氮甲烷分解产物比例的影响。
  • Torquoselectivity in the electrocyclic conversion of benzocyclobutenes to o-xylylenes
    作者:Charles W. Jefford、Gerald Bernardinelli、Ying Wang、David C. Spellmeyer、Andrzej Buda、K. N. Houk
    DOI:10.1021/ja00030a005
    日期:1992.2
    conrotatory electrocyclic opening of benzocyclobutene to o-xylylene was studied by means of ab initio molecular orbital calculations. The theory developed earlier to predict the torquoselectivity of ring opening of J-substituted cyclobutenes was found to be applicable. Experimentally, the ring opening of several 7-substituted benzocyclobutenes, such as the cyano, methoxycarbonyl, and formyl derivatives was
    通过从头算分子轨道计算研究了苯并环丁烯向邻二甲苯的旋转电环开环。发现较早开发的用于预测 J-取代环丁烯开环扭矩选择性的理论是适用的。通过实验,研究了几种 7-取代的苯并环丁烯的开环,例如氰基、甲氧基羰基和甲酰基衍生物。得到邻二甲苯,其中氰基或酯基向外旋转,而甲酰基向内旋转
  • [EN] TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS<br/>[FR] DERIVES DE LACTAME TRICYCLIQUE UTILISES EN TANT QU'INHIBITEURS DE 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2006024628A1
    公开(公告)日:2006-03-09
    Compounds of formulae (I) and (I bis) are useful as 11BETA-HSD1 inhibitors for treatment of obesity.
    式(I)和(I bis)的化合物可用作11BETA-HSD1抑制剂,用于治疗肥胖。
  • Tricyclic Lactam Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors
    申请人:Jaraskova Libuse
    公开号:US20080214597A1
    公开(公告)日:2008-09-04
    the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein X represents C or N; Y represents C or N; L represents a methyl or a direct bond; Z 1 represents a direct bond, C 1-2 alkyl- or a divalent radical of formula —CH 2 —CH═ (a) or —CH═ (b); Z 2 represents a direct bond, C 1-2 alkyl- or a divalent radical of formula —CH 2 —CH═ (a) or —CH═ (b); R 1 represents hydrogen, halo, cyano, amino, phenyl, hydroxy, C 1-4 alkyloxycarbonyl, hydroxycarbonyl, NR 3 R 4 or C 1-4 alkyl optionally substituted with one or more substituents selected from hydroxycarbonyl, phenyl, C 1-4 alkyloxy or NR 5 R 6 or R 1 represents C 1-4 alkyloxy- optionally substituted with one or more substituents selected from hydroxycarbonyl, phenyl, C 1-4 alkyloxy or NR 7 R 8 ; R 2 represents hydrogen, halo, C 1-4 alkyl or C 1-4 alkyloxy-; R 3 and R 4 each independently represent hydrogen, C 1-4 alkyl or C 1-4 alkylcarbonyl-; R 5 and R 6 each independently represent hydrogen, C 1-4 alkyl or C 1-4 alkylcarbonyl-; R 7 and R 8 each independently represent hydrogen, C 1-4 alkyl or C 1-4 alkylcarbonyl-; A represents phenyl or a monocyclic heterocycle selected from the group consisting of thiophenyl, furanyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, pyrridinyl, pyridazinyl, pyrimidinyl and piperazinyl.
    N-氧化物形式,其药学上可以接受的加成盐和立体化学异构体形式,其中X代表C或N;Y代表C或N;L代表甲基或直接键;Z1代表直接键,C1-2烷基或公式—CH2—CH═(a)或—CH═(b)的二价基团;Z2代表直接键,C1-2烷基或公式—CH2—CH═(a)或—CH═(b)的二价基团;R1代表氢,卤素,氰基,氨基,苯基,羟基,C1-4烷氧羰基,羟羰基,NR3R4或C1-4烷基,可选地被选自羟羰基,苯基,C1-4烷氧基或NR5R6的一个或多个取代基取代,或R1代表C1-4烷氧基,可选地被选自羟羰基,苯基,C1-4烷氧基或NR7R8的一个或多个取代基取代;R2代表氢,卤素,C1-4烷基或C1-4烷氧基;R3和R4各自独立地代表氢,C1-4烷基或C1-4烷基羰基;R5和R6各自独立地代表氢,C1-4烷基或C1-4烷基羰基;R7和R8各自独立地代表氢,C1-4烷基或C1-4烷基羰基;A代表苯基或从噻吩基,呋喃基,噁唑基,噻唑基,咪唑基,异噁唑基,异噻唑基,吡啶基,吡嗪基,嘧啶基和哌嗪基中选择的单环杂环。
查看更多

同类化合物

2,9-二(2-苯乙基)蒽并[2,1,9-DEF:6,5,10-D’E’F’]二异喹啉-1,3,8,10(2H,9H)-四酮 (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-盐酸沙丁胺醇 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3,3''-双([[1,1''-联苯]-4-基)-[1,1''-联萘]-2,2''-二醇 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,5R)-3,3a,8,8a-四氢茚并[1,2-d]-1,2,3-氧杂噻唑-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aS,8aR)-2-(吡啶-2-基)-8,8a-二氢-3aH-茚并[1,2-d]恶唑 (3aS,3''aS,8aR,8''aR)-2,2''-环戊二烯双[3a,8a-二氢-8H-茚并[1,2-d]恶唑] (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3S,3aR)-2-(3-氯-4-氰基苯基)-3-环戊基-3,3a,4,5-四氢-2H-苯并[g]吲唑-7-羧酸 (3R,3’’R,4S,4’’S,11bS,11’’bS)-(+)-4,4’’-二叔丁基-4,4’’,5,5’’-四氢-3,3’’-联-3H-二萘酚[2,1-c:1’’,2’’-e]膦(S)-BINAPINE (3-三苯基甲氨基甲基)吡啶 (3-[(E)-1-氰基-2-乙氧基-2-hydroxyethenyl]-1-氧代-1H-茚-2-甲酰胺) (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,4S)-Fmoc-4-三氟甲基吡咯烷-2-羧酸 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-硝基苯基)磷酸三酰胺 (2-氯-6-羟基苯基)硼酸 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1α,1'R,4β)-4-甲氧基-5''-甲基-6'-[5-(1-丙炔基-1)-3-吡啶基]双螺[环己烷-1,2'-[2H]indene (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1R,1′R,2S,2′S)-2,2′-二叔丁基-2,3,2′,3′-四氢-1H,1′H-(1,1′)二异磷哚